AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1557640
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (initial dosage of 5-FU 600 mg/m2)
Trial: 1557640
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (after reduction of 5-FU dosage to 500 mg/m2)
Trial: 1756437
Drug: Indomethacin, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 150 mg daily for 3 days
Trial: 31107913
Drug: Tenofovir (TFV)
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir (TFV) IVR (8-10 mg/day)
Trial: 21929562
Drug: PLC 1
RxNorm normalized name: Phospholipase C 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLC 1 g/day
Trial: 21929562
Drug: PLC 2
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PLC 2 g/day
Trial: 10914843
Drug: Prednisone (4.37
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (4.37 mg daily)
Trial: 1428189
Drug: Loracarbef (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loracarbef (200 mg capsule twice daily or 15 mg/kg/day oral suspension in two divided doses up to a maximum of 375 mg/day)
Trial: 1428189
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (250 mg capsule four times daily or 20 mg/kg/day suspension in four divided doses up to a maximum of 500 mg/day)
Trial: 3880876
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of serum concentrations of estradiol, progesterone, dehydroepiandrosterone sulfate, and testosterone before and after treatment
Trial: 29520956
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate solution (2%) (NP-CHX)
Trial: 29520956
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate solution (2%) (P-CHX)
Trial: 24901365
Drug: Dapivirine vaginal
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine vaginal ring (25 mg) used continuously for 28 days
Trial: 15629415
Drug: Oxymorphone ER
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone ER (10 to 110 mg)
Trial: 15629415
Drug: Oxycodone CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone CR (20 to 220 mg)
Trial: 12833472
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa for the treatment of anemia
Trial: 7073809
Drug: Diflorasone diacetate
RxNorm normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diflorasone diacetate ointment 0.05%
Trial: 7073809
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate ointment 0.05%
Trial: 3619423
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg intravenously
Trial: 3619423
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg orally
Trial: 8617581
Drug: Didemnin B
RxNorm normalized name: Dehydrodidemnin B
DrugBank: Plitidepsin (DB04977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didemnin B at 3.5 mg/m2
Trial: 8617581
Drug: Didemnin B
RxNorm normalized name: Dehydrodidemnin B
DrugBank: Plitidepsin (DB04977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didemnin B at 6.3 mg/m2
Trial: 2666024
Drug: Oral beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beta-carotene (50 mg/day)
Trial: 987254
Drug: Fusaric acid
RxNorm normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusaric acid calcium salt (5.1 mg/Kg to 6.0 mg/Kg)
Trial: 28489737
Drug: Oral use
RxNorm normalized name: ACETEST TAB (NOT FOR ORAL USE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use of montelukast sodium
Trial: 28489737
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray of mometasone furoate
Trial: 28489737
Drug: Oral use
RxNorm normalized name: ACETEST TAB (NOT FOR ORAL USE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use of montelukast sodium + nasal spray of mometasone furoate
Trial: 25836732
Drug: Telepractice delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telepractice delivery of flow phonation voice therapy exercises
Trial: 25836732
Drug: In-person delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-person delivery of flow phonation voice therapy exercises
Trial: 19482892
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection guided by electrical stimulation plus physiotherapy
Trial: 19482892
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection guided by palpation plus physiotherapy
Trial: 12601540
Drug: No salvage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No salvage therapy (Control)
Trial: 11938859
Drug: Lumbricus solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbricus solution applied to wound surface after hemorrhoidectomy
Trial: 11938859
Drug: Lumbricus solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbricus solution
Trial: 11938859
Drug: Lumbricus preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbricus preparation
Trial: 27431239
Drug: Multimedia intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimedia intervention delivered daily from Day 1 to Day 5 via iPad™, comprising information on the goals of care for each day following surgery.
Trial: 12865917
Drug: Stopped hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stopped hormone replacement therapy (HRT)
Trial: 1857480
Drug: Desferrioxamine (DFO)
RxNorm normalized name: DFO
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (DFO) at a dose of 20-30 mg/kg
Trial: 1857480
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (r‐HuEPO) at a dose of 40 units/kg/dialysis i.v.
Trial: 31250239
Drug: Treatment-as-usual (n=44)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (n=44)
Trial: 29905904
Drug: Beta-alanine (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (6.4 g day-1)
Trial: 24931055
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to daily caloric intake goals
Trial: 19994686
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (oral Diclofenac sodium and intramuscular Methotrexate)
Trial: 14731164
Drug: Ritonavir 200
RxNorm normalized name: lopinavir-ritonavir 200 mg-50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 200 mg bid
Trial: 14731164
Drug: Lopinavir 400
RxNorm normalized name: LOPINAVIR 400MG/RITONAVIR 100MG/5ML SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir 400 mg bid added on day 15
Trial: 7963907
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg rifampin (RMP)
Trial: 7963907
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg rifampin (RMP)
Trial: 7963907
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of rifampin (RMP)
Trial: 7963907
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of rifampin (RMP)
Trial: 3115136
Drug: Ro 15-1788
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15-1788 (1 ml = 0.1 mg active drug)
Trial: 26823128
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kg) in CC trial
Trial: 26823128
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kg) in PC trial
Trial: 20306851
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (control group, n = 66)
Trial: 15749459
Drug: 10‐mg amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg amlodipine tablet formulation
Trial: 12739704
Drug: Loperamide (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (8 mg + 4 mg + 4 mg, administered 12 h and 2 h before, and 7 h after the start of the recording)
Trial: 8703558
Drug: TA-0910 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-0910 (10 mg or 20 mg daily)
Trial: 30729947
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CNT) with no antibacterial agents
Trial: 29130810
Drug: Intravenous 1.26%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 1.26% sodium bicarbonate
Trial: 29130810
Drug: Intravenous 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9% sodium chloride
Trial: 30466822
Drug: Oral acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetylcysteine
Trial: 22976492
Drug: ACH-1625 (monotherapy)
RxNorm normalized name: ACh
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACH-1625 (monotherapy)
Trial: 20236198
Drug: Pale sulfonated
RxNorm normalized name: pale dock pollen extract
DrugBank: Rumex altissimus pollen (DB10901)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pale sulfonated shale oil (PSSO) cream 4%
Trial: 17662293
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of red wine (4.0+/‐0.4 dl)
Trial: 17662293
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of red wine (8.1+/‐0.9 dl)
Trial: 17662293
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of red wine
Trial: 15933926
Drug: 4 l
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 l polyethylene glycol (PEG)
Trial: 15933926
Drug: 2 l
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 l PEG plus 10 mg Bisacodyl
Trial: 15933926
Drug: 90 ml
RxNorm normalized name: 190 ML Infugem 10 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 ml sodium phosphate
Trial: 8908380
Drug: GLP-1 treatment
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 treatment with regular insulin from day 8 to 12 and GLP-1 only at meals on days 13 and 14
Trial: 23764734
Drug: GLP-1 treatment
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 treatment
Trial: 8908380
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (insulin only)
Trial: 6419594
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg auranofin daily
Trial: 6419594
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg auranofin daily
Trial: 6419594
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg auranofin daily
Trial: 6419594
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg auranofin daily
Trial: 28912054
Drug: Pharmacist interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist interventions including patient, laboratory, and individualized CV risk assessments; treatment recommendations; prescription adaptations; and regular monthly follow-up for 3 months.
Trial: 27648286
Drug: Technosphere inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere inhaled insulin (TI) during URTI
Trial: 26718805
Drug: Technosphere inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere inhaled insulin (TI) during meal challenges
Trial: 18537977
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of anti-PMS1 antibody
Trial: 18537977
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HLA-DR15, no PNH-type cells, no anti-PMS1 antibody)
Trial: 17767017
Drug: Leukocyte therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte therapy (immunization by isolated lymphocytes from husbands, 50 to 100 million washed and resuspended mononuclear cells injected by I.V., S.C., and I.D. route, repeated immunization if needed)
Trial: 17767017
Drug: Leukocyte therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte therapy in primary aborters
Trial: 17767017
Drug: Leukocyte therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte therapy in secondary aborters
Trial: 10894866
Drug: Standard-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose regimen (arm A): doxorubicin (50 mg/m² on day 1) and ifosfamide (5 g/m² on day 1)
Trial: 10894866
Drug: Intensified regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified regimen (arm B): doxorubicin (75 mg/m² on day 1), ifosfamide (5 g/m² on day 1), and rhGM-CSF (250 microgram/m² on days 3 to 16)
Trial: 6139040
Drug: dexchlorpheniramine maleate
RxNorm normalized name: Dexchlorpheniramine Maleate
DrugBank: Dexchlorpheniramine (DB13679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dexchlorpheniramine maleate sustained release tablets (6 mg b.d.)
Trial: 6139040
Drug: budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide nasal spray (200 micrograms b.d.)
Trial: 27777180
Drug: Daily inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily inhaled corticosteroids (ICSs)
Trial: 27777180
Drug: Daily leukotriene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily leukotriene receptor antagonists
Trial: 27777180
Drug: As-needed ICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed ICS treatment coadministered with albuterol
Trial: 19021920
Drug: Organically produced
RxNorm normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organically produced carrots (200 g/d; 2 weeks)
Trial: 19021920
Drug: Conventionally produced
RxNorm normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally produced carrots (200 g/d; 2 weeks)
Trial: 9817267
Drug: Epirubicin (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (cumulative doses greater than 950 mg/m2)
Trial: 25955227
Drug: Levothyroxine (L-T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (L-T4) treatment for 6 months
Trial: 17685736
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (75 mg/day to 300 mg/day)
Trial: 14717655
Drug: Hypoglycaemia (2.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia (2.7 mmol/l)
Trial: 14717655
Drug: Normoglycaemia (4.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycaemia (4.7 mmol/l)
Trial: 11591895
Drug: Once-daily administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily administration of gentamicin (6.5 mg/kg starting dose, adjusted to 7.3 mg/kg per day)
Trial: 11591895
Drug: Multiple-daily administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-daily administration of gentamicin (6.8 mg/kg per day)
Trial: 7992810
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of Tc-99m pertechnetate at acupuncture point K-3 (Taixi)
Trial: 7992810
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of Tc-99m pertechnetate at other acupuncture points (APs)
Trial: 7992810
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of Tc-99m pertechnetate at non-acupuncture points (NAPs)
Trial: 2659954
Drug: Org OD
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org OD 14 (new steroid drug taken orally)
Trial: 30283029
Drug: Ketamine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 1.0 mg/kg
Trial: 26202811
Drug: Alteplase plus
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase plus oral fingolimod 0.5 mg daily for 3 consecutive days
Trial: 22841937
Drug: RapidArc (Volumetric-modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RapidArc (Volumetric-modulated arc therapy)
Trial: 22028623
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment with gemcitabine and bevacizumab
Trial: 12382151
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) 2.0 g/kg given over 24 or 48 hours
Trial: 9651568
Drug: Acipimox (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (3 X 250 mg daily for 12 weeks)
Trial: 9651568
Drug: Acipimox (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (3 X 250 mg daily for 12 weeks) in a subgroup of 8 patients with baseline TG > 4 mmol L-1
Trial: 2539830
Drug: Cod liver
RxNorm normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod liver oil (CLO) supplementation (25 ml daily for 8 weeks)
Trial: 368817
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of chlorpromazine
Trial: 368817
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of amitriptyline
Trial: 368817
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg of dextroamphetamine sulfate
Trial: 28439716
Drug: First-generation antipsychotic
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation antipsychotic drugs
Trial: 23102531
Drug: Aggressive fever
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive fever control strategy (acetaminophen, physical cooling); acetaminophen dose: 2275 mg
Trial: 23102531
Drug: Permissive fever
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permissive fever control strategy; acetaminophen dose: 0 mg
Trial: 22132651
Drug: Combined VHA/VHB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined VHA/VHB vaccine (HAB group)
Trial: 22132651
Drug: Concomitant VHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant VHA and VHB vaccines (ENG+HAV group)
Trial: 22132651
Drug: Concomitant VHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant VHA and VHB vaccines (HBVX+VAQ group)
Trial: 19368782
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated subunit influenza vaccine Influvac®
Trial: 16344276
Drug: Booklet about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booklet about chemotherapy (n = 72)
Trial: 9032742
Drug: 17 beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta‐estradiol 2 mg plus norethisterone acetate 1 mg
Trial: 8060436
Drug: Albuterol powder
RxNorm normalized name: albuterol Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol powder 200 micrograms inhaled every 4 hours (Group I)